Dominant-negative activity of a Brca1 truncation mutant: effects on proliferation, tumorigenicity in vivo, and chemosensitivity in a mouse ovarian cancer cell line.
about
BRCAness: finding the Achilles heel in ovarian cancerThe Icelandic founder mutation BRCA2 999del5: analysis of expressionFine tuning chemotherapy to match BRCA1 statusChemoresistance and targeted therapies in ovarian and endometrial cancersOrganizing principles of mammalian nonsense-mediated mRNA decayTurnover of BRCA1 involves in radiation-induced apoptosis.Enhanced sensitivity to cisplatin and gemcitabine in Brca1-deficient murine mammary epithelial cells.MicroRNA-mediated repression of nonsense mRNAs.BRCA1 185delAG Mutation Enhances Interleukin-1β Expression in Ovarian Surface Epithelial Cells.BRCA1 Expression is an Important Biomarker for Chemosensitivity: Suppression of BRCA1 Increases the Apoptosis via Up-regulation of p53 and p21 During Cisplatin Treatment in Ovarian Cancer CellsBRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cellsGermline BRCA mutation does not prevent response to taxane-based therapy for the treatment of castration-resistant prostate cancer.BRCA1 as a Therapeutic Target in Sporadic Epithelial Ovarian Cancer.Phenylbutyrate interferes with the Fanconi anemia and BRCA pathway and sensitizes head and neck cancer cells to cisplatin.Computational Investigation of Homologous Recombination DNA Repair Deficiency in Sporadic Breast Cancer.Predictive value of BRCA1/2 mRNA expression for response to neoadjuvant chemotherapy in BRCA-negative breast cancers.Nonsense-mediated mRNA Decay and Cancer.
P2860
Q24630872-21133654-ED20-42D3-84E0-CB654A5B53A2Q24805817-7952CC2C-F548-4C89-B46E-E7717151CB30Q27694529-61EAC9C8-54DA-4E24-9179-235B40352EB3Q28073246-3A705230-42C5-4DD5-85A4-53B824D3E646Q28302705-1AAAFD31-97EB-4707-9ABB-D54DFE9CB772Q33789102-CFB347DC-9EE4-42FB-9B3F-6E299066FBF6Q33965570-3AD0E2B4-E7C2-456E-879A-F4EBC61423C1Q35176520-8EDA787E-8B70-4B86-8F71-97501A7E7D90Q36017531-B00CD9C0-B258-47F3-9BE4-CFA6C4973ECFQ37277941-3FD6E36F-6B23-460A-86B7-673CCD57B344Q37355031-3AC9BA6C-D96D-4362-BDAE-5712A95B3AD0Q37677557-680EBC47-AB8B-404E-B5D1-B041AE0E4E54Q42061759-03BCFA28-7E59-4822-9F7F-B110C157AF5FQ43089139-8078F6D0-C688-4C8F-8FA1-A6861FECBBE6Q47145727-7E633557-D7F6-4466-8636-8C047A097BD9Q48163701-6EE3DAA4-4712-40D7-A79C-8A350FA38D26Q50091118-B3D1FC5D-8142-40D1-A9C9-735DEA6BF9DD
P2860
Dominant-negative activity of a Brca1 truncation mutant: effects on proliferation, tumorigenicity in vivo, and chemosensitivity in a mouse ovarian cancer cell line.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
Dominant-negative activity of ...... ouse ovarian cancer cell line.
@en
type
label
Dominant-negative activity of ...... ouse ovarian cancer cell line.
@en
prefLabel
Dominant-negative activity of ...... ouse ovarian cancer cell line.
@en
P2093
P1476
Dominant-negative activity of ...... mouse ovarian cancer cell line
@en
P2093
Stephane Lafarge
Valerie Sylvain
Yves-Jean Bignon
P304
P577
2002-04-01T00:00:00Z